Neil K. Warma - 03 Feb 2026 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: PMN
Reported as of: 03 Feb 2026
Net transaction value: +$75,000
SEC form: 4
Accepted by SEC: 05 Feb 2026, 20:39:31 UTC
Prior SEC filing: 24 Sep 2025
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Max A. Milbury, Attorney in Fact for Neil Warma

Key filing fact

Neil K. Warma filed Form 4 for ProMIS Neurosciences Inc. (PMN) on 05 Feb 2026.

Key facts

This page summarizes Neil K. Warma's Form 4 filing for ProMIS Neurosciences Inc. (PMN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2026, 20:39.

Change

Previous filing in this sequence was filed on 24 Sep 2025.
Current net transaction value: +$75,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001437911 Primary reporting owner

Warma Neil K

Relationship: Chief Executive Officer, Director
Address: C/O PROMIS NEUROSCIENCES INC., 1920 YONGE STREET, SUITE 200, TORONTO, ONTARIO, CANADA
Signature: /s/ Max A. Milbury, Attorney in Fact for Neil Warma
Signature date: 05 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PMN transaction

Common Shares

Award

Transaction value: $75,000
Shares: +6,183
Change %
Price: $12.13
Shares after: 6,183
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMN transaction Derivative

Warrants to purchase Common Shares

Award

Transaction value
Shares: +6,183
Change %
Price
Shares after: 6,183
Date: 03 Feb 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 6,183
Exercise price: $14.40
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

Footnote F2

The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.